$OPCH
Option Care Health, Inc.

2023 Q3 Form 10-Q Financial Statement

#000101473923000034 Filed on July 27, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.093B $1.069B
YoY Change 7.06% 9.0%
Cost Of Revenue $838.7M $818.2M
YoY Change 4.46% 7.11%
Gross Profit $254.3M $250.8M
YoY Change 16.64% 15.64%
Gross Profit Margin 23.26% 23.46%
Selling, General & Admin $158.2M $153.6M
YoY Change 11.41% 8.31%
% of Gross Profit 62.22% 61.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $15.01M $15.58M
YoY Change -1.72% -2.87%
% of Gross Profit 5.9% 6.21%
Operating Expenses $173.2M $168.5M
YoY Change 10.13% 6.74%
Operating Profit $81.05M $82.37M
YoY Change 33.48% 39.43%
Interest Expense $11.79M -$11.80M
YoY Change -15.8% -192.43%
% of Operating Profit 14.54% -14.32%
Other Income/Expense, Net -$449.0K $84.94M
YoY Change -111.55% 8493400.0%
Pretax Income $70.09M $155.5M
YoY Change 34.57% 226.43%
Income Tax $13.80M $41.10M
% Of Pretax Income 19.69% 26.43%
Net Earnings $56.30M $114.4M
YoY Change 45.02% 237.18%
Net Earnings / Revenue 5.15% 10.7%
Basic Earnings Per Share $0.31 $0.64
Diluted Earnings Per Share $0.31 $0.63
COMMON SHARES
Basic Shares Outstanding 179.9M shares 179.8M shares
Diluted Shares Outstanding 180.5M shares 181.2M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $386.5M $441.2M
YoY Change 51.29% 116.21%
Cash & Equivalents $386.5M $441.2M
Short-Term Investments
Other Short-Term Assets $95.50M $97.63M
YoY Change -0.82% 24.28%
Inventory $251.4M $262.9M
Prepaid Expenses
Receivables $383.0M $396.5M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.116B $1.198B
YoY Change 17.26% 36.61%
LONG-TERM ASSETS
Property, Plant & Equipment $108.0M $186.6M
YoY Change 12.09% 77.32%
Goodwill $1.540B $1.541B
YoY Change 0.47% 1.87%
Intangibles
YoY Change
Long-Term Investments $19.50M $19.70M
YoY Change -10.14% -9.22%
Other Assets $51.40M $23.26M
YoY Change 9.31% -41.95%
Total Long-Term Assets $2.127B $2.123B
YoY Change 0.28% 0.66%
TOTAL ASSETS
Total Short-Term Assets $1.116B $1.198B
Total Long-Term Assets $2.127B $2.123B
Total Assets $3.244B $3.321B
YoY Change 5.54% 11.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $429.5M $467.7M
YoY Change 4.83% 22.9%
Accrued Expenses $188.5M $194.8M
YoY Change 10.19% 15.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $6.000M $6.000M
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $624.1M $668.5M
YoY Change 6.35% 20.38%
LONG-TERM LIABILITIES
Long-Term Debt $1.057B $1.057B
YoY Change -0.15% -0.15%
Other Long-Term Liabilities $3.089M $84.23M
YoY Change -61.67% 526.45%
Total Long-Term Liabilities $1.179B $1.142B
YoY Change 2.64% -0.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $624.1M $668.5M
Total Long-Term Liabilities $1.179B $1.142B
Total Liabilities $1.804B $1.846B
YoY Change 3.89% 8.5%
SHAREHOLDERS EQUITY
Retained Earnings $400.3M $344.0M
YoY Change 180.16% 230.58%
Common Stock $1.198B $1.188B
YoY Change 2.18% 1.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.440B $1.475B
YoY Change
Total Liabilities & Shareholders Equity $3.244B $3.321B
YoY Change 5.54% 11.22%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $56.30M $114.4M
YoY Change 45.02% 237.18%
Depreciation, Depletion And Amortization $15.01M $15.58M
YoY Change -1.72% -2.87%
Cash From Operating Activities $61.00M $169.5M
YoY Change -30.0% 62.59%
INVESTING ACTIVITIES
Capital Expenditures $8.400M $7.794M
YoY Change -219.05% -265.97%
Acquisitions
YoY Change
Other Investing Activities -$5.800M -$12.86M
YoY Change -78.85% -78.54%
Cash From Investing Activities -$14.30M -$20.65M
YoY Change -58.52% -68.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -101.4M -5.497M
YoY Change 8064.25% -129.29%
NET CHANGE
Cash From Operating Activities 61.00M 169.5M
Cash From Investing Activities -14.30M -20.65M
Cash From Financing Activities -101.4M -5.497M
Net Change In Cash -54.70M 143.4M
YoY Change -206.37% 145.34%
FREE CASH FLOW
Cash From Operating Activities $61.00M $169.5M
Capital Expenditures $8.400M $7.794M
Free Cash Flow $52.60M $161.7M
YoY Change -44.16% 48.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26409000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69952000 usd
bios Proceeds From Payments For Stock Options Exercised Restricted Stock Vested And Tax Withholding
ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding
-2149000 usd
bios Proceeds From Payments For Stock Options Exercised Restricted Stock Vested And Tax Withholding
ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding
523000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
20098000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
75000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-5750000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-85899000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17621000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
146980000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
84623000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
294186000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119423000 usd
us-gaap Interest Paid Net
InterestPaidNet
33991000 usd
us-gaap Interest Paid Net
InterestPaidNet
21793000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
21786000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4966000 usd
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
13231000 usd
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
12435000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1175886000 usd
CY2022Q1 bios Stock Issued Value Restricted Stock Stock Options Exercised And Tax Withholdings
StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings
-355000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4178000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
30275000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11070000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1221764000 usd
CY2022Q2 bios Stock Issued Value Restricted Stock Stock Options Exercised And Tax Withholdings
StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings
-168000 usd
CY2022Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
20098000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4398000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
33929000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4637000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1284994000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1386103000 usd
CY2023Q1 bios Stock Issued Value Restricted Stock Stock Options Exercised And Tax Withholdings
StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings
1902000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5988000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
75735000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39208000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3443000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1350219000 usd
CY2023Q2 bios Stock Issued Value Restricted Stock Stock Options Exercised And Tax Withholdings
StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings
247000 usd
CY2023Q2 bios Stock Repurchased During Period Value Tax Effect
StockRepurchasedDuringPeriodValueTaxEffect
32000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
114403000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3291000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1475383000 usd
CY2023Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2475166 shares
CY2023Q2 bios Number Of Service Locations
NumberOfServiceLocations
94 pharmacy
CY2023Q2 bios Number Of Infusion Sites
NumberOfInfusionSites
76 suite
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
58200000 usd
CY2022Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
53400000 usd
CY2023Q2 us-gaap Equity Method Investments
EquityMethodInvestments
19700000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
19400000 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1400000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2800000 usd
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1300000 usd
CY2022Q2 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1000000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1000000 usd
CY2023Q2 us-gaap Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cost Expensed
BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
21100000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1069072000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
980820000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2084920000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1896604000 usd
bios Termination Fee Income Tax Effect
TerminationFeeIncomeTaxEffect
22100000 usd
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.264
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.268
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.264
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.268
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24700000 usd
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.288
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.278
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.288
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.278
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13100000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
56100000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24700000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
114403000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
33929000 usd
us-gaap Net Income Loss
NetIncomeLoss
153611000 usd
us-gaap Net Income Loss
NetIncomeLoss
64204000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179807000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180621000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180531000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180293000 shares
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1434000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
997000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1400000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
883000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
181241000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
181618000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
181931000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
181176000 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
7300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
14500000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
7400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
14800000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0580
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
15611000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
21744000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
19350000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16562000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13500000 usd
CY2023Q2 bios Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
38205000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
124972000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25085000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
99887000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16800000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8400000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
241088000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
230289000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
134311000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
121968000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106777000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
108321000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
6968000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
8604000 usd
us-gaap Depreciation
Depreciation
13690000 usd
us-gaap Depreciation
Depreciation
17050000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1533424000 usd
CY2023Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
145000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1533569000 usd
CY2023Q2 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
6998000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
1540567000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
554527000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
549066000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
201934000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
184951000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
352593000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
364115000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8500000 usd
CY2023Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
30.30
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8700000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16200000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6000000 usd
CY2023Q2 bios Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1064000000 usd
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1091000000 usd
CY2023Q2 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1063391000 usd
CY2023Q2 us-gaap Derivative Assets
DerivativeAssets
28067000 usd
CY2022Q4 us-gaap Derivative Assets
DerivativeAssets
28268000 usd
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
75000000 usd
CY2023Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
175000000 usd
CY2023Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2475166 shares
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
75000000 usd
CY2023Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2475166 shares
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001014739-23-000034-index-headers.html Edgar Link pending
0001014739-23-000034-index.html Edgar Link pending
0001014739-23-000034.txt Edgar Link pending
0001014739-23-000034-xbrl.zip Edgar Link pending
bios-20230630.htm Edgar Link pending
bios-20230630.xsd Edgar Link pending
bios-20230630_g1.jpg Edgar Link pending
exhibit102-optioncarexamen.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
opch-ex311x2023063010xq.htm Edgar Link pending
opch-ex312x2023063010xq.htm Edgar Link pending
opch-ex321x2023063010xq.htm Edgar Link pending
opch-ex322x2023063010xq.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
bios-20230630_def.xml Edgar Link unprocessable
bios-20230630_pre.xml Edgar Link unprocessable
bios-20230630_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bios-20230630_cal.xml Edgar Link unprocessable
bios-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable